Eight to 12 percent of Americans have periodontal disease serious enough to require some type of advanced treatment, such as surgery. Left untreated, the condition can lead to tooth loss.
The breakthrough technology – a polymer-based drug delivery system that may be implanted in pockets between the teeth and the gum – developed at Rutgers, The State University of New Jersey, was presented at the 232nd National Meeting of the American Chemical Society in San Francisco by Michelle Johnson, a graduate student in the research group of paper co-author Kathryn Uhrich, a professor of chemistry and chemical biology at Rutgers.
"There has never been anything like this available to clinicians and it will certainly find a very prominent role in periodontal therapy in the future," said Mark Reynolds, chair of the department of periodontics at the University of Maryland Dental School, who collaborates with Uhrich on the research.
The new polymer or "plastic" material, when inserted between tooth and diseased gum, treats the bacterial infection, inflammation and pain with pharmaceuticals incorporated into the material itself, Johnson explained. It employs salicylic acid, the active ingredient in aspirin, for the swelling and discomfort, and three antimicrobials each with a different release rate – compounds of clindamycin, chlorhexidrine and minocycline.
Once implanted, the polymer gradually breaks down to release the salicylic acid, which relieves pain and reduces inflammation, and the antimicrobials which inhibit infection at a sustained pace, Uhrich added.
Periodontal disease occurs when plaque that forms on the tooth surface spreads and grows below the gum line. The plaque carries with it bacteria that can irritate, inflame and eventually destroy the tissues and bone that support the teeth. Spaces or pockets form between the teeth and gums and become sites of infection which can damage the supporting structures of the teeth.
Reynolds explained that after removing the damaged tissue, periodontists often try to separate the gum tissue from the bone and tooth structure using barrier materials that remain in place for about six weeks to facilitate healing and tissue regeneration.
"The polymers that Kathryn Uhrich and her team have pioneered and developed are unique in that they can serve as barriers while also repressing any inflammatory response, setting the stage for nature to not only heal these areas, but also to regenerate the tissues that have been lost to the disease," Reynolds said.
Reynolds is testing the new biomaterial in a number of animal systems to assess tissue reactions and better define the timeline of its decomposition and drug release. He says that human clinical trials may be two or more years away depending on approvals from the U.S. Food and Drug Administration.
Joseph Blumberg | EurekAlert!
Speed data for the brain’s navigation system
06.12.2016 | Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
06.12.2016 | Health and Medicine
06.12.2016 | Life Sciences
05.12.2016 | Power and Electrical Engineering